EGFR inhibitor

EGFR inhibitors

EGFR inhibitors are,Acts on the epidermal growth factor receptor (EGFR) on the surface of cancer cellsand are molecularly targeted drugs that suppress cancer growth by blocking signaling pathways involved in cell proliferation and survival. They are used when abnormal EGFR function is implicated in cancer development and progression, and high therapeutic efficacy can be expected in patients with specific gene mutations. Note that there are several types of EGFR inhibitors.Tyrosine kinase inhibitors (EGFR-TKIs) are one example.It exerts an antitumor effect by inhibiting the tyrosine kinase activity within the cell of EGFR.

Representative examples of EGFR inhibitors

There are multiple types of EGFR inhibitors, classified by their action characteristics and generation of development. Here, we will briefly introduce the characteristics of representative EGFR inhibitors widely used in clinical practice.

Gefitinib

• Target: Expressed on cancer cellsEpidermal growth factor receptor (EGFR) tyrosine kinaseIt is a first-generation EGFR tyrosine kinase inhibitor that targets. It is particularly used for non-small cell lung cancer with EGFR gene mutations.
• Mechanism of Action: Selectively inhibits the tyrosine kinase activity of EGFR, suppressing signal transduction involved in cell proliferation and survival. As a result, it suppresses cancer cell proliferation and induces apoptosis (programmed cell death), thereby exerting an antitumor effect.

Erlotinib

• Target: Expressed on cancer cellsEpidermal growth factor receptor (EGFR) tyrosine kinaseIt is a first-generation EGFR tyrosine kinase inhibitor targeting . It is used for EGFR gene mutation-positive non-small cell lung cancer and some pancreatic cancers.
• Mechanism of Action: It selectively binds to the intracellular tyrosine kinase domain of EGFR and inhibits its activity, thereby suppressing signal transduction involved in cell proliferation and survival. As a result, it inhibits the proliferation of cancer cells and exhibits an antitumor effect.

Osimertinib

• TargetEGFR tyrosine kinase with EGFR gene mutation and T790M mutation as a resistance mutation.It is a third-generation EGFR tyrosine kinase inhibitor that targets _. It shows high selectivity against mutant EGFR and is used for EGFR gene mutation-positive non-small cell lung cancer.
• Mechanism of action: It irreversibly binds to the tyrosine kinase domain of EGFR and inhibits its activity, thereby blocking signaling pathways involved in cell proliferation and survival. Furthermore, it also acts on the T790M mutation, which is a major cause of resistance to first and second-generation EGFR inhibitors, and suppresses the proliferation of cancer cells.

Key challenges in EGFR inhibitor development

Overcoming acquired resistance

With EGFR inhibitors,Resistance mutations such as T790M and C797S emerge during treatmentand drug efficacy may be reduced. Non-clinical studies using resistant cell lines and organoids play an important role in overcoming this.

Addressing EGFR mutations differently for each patient

With EGFR inhibitors,Drug selection based on patient-specific EGFR mutations such as exon 19 deletions and L858Ris important. Therefore, evaluation using patient-derived models and the development of highly accurate biomarkers are required.

How to predict drug efficacy in humans

EGFR inhibitors affect not only cancer cells but also the skin, the gastrointestinal tract, and other areas such asIt also acts on EGFR in normal tissue.Therefore, on-target toxicities such as rash and diarrhea may occur. For this reason, in addition to safety and toxicity evaluations, it is important to establish disease models and efficacy evaluation systems that can more accurately predict human responses, thereby enhancing human translatability.

Non-clinical evaluation required for EGFR inhibitors

Build an evaluation system capable of reproducing resistance mechanisms.

Resistance acquisition due to mutations such as T790M and C797S in EGFR inhibitors is a major challenge. Standard cell lines cannot fully reproduce clinical resistance, therefore,Evaluate using a combination of resistant cell lines, patient-derived organoids, and PDX models.It is important to utilize each model appropriately according to the development stage, taking into account the characteristics of each model. This allows for the evaluation of resistance mechanisms and the efficacy of next-generation drug candidates under conditions more closely resembling actual clinical practice.

To evaluate the effect on the target in a multifaceted way.

Even if binding to the target is confirmed, that alone does not necessarily guarantee sufficient therapeutic efficacy. Therefore,In addition to confirming target binding by target engagement, evaluate mechanism of action and drug efficacy with biomarkers.It is important to comprehensively examine the anti-tumor effects and signal inhibition through pharmacological and pharmacological studies. Combining multiple evaluation indicators allows for a more appropriate assessment of candidate drugs.

Evaluate pharmacokinetics and pharmacodynamics in combination.

A possible reason for lack of therapeutic effect is not the insufficient action of the drug itself, but rather that it may not be sufficiently reaching the target tissue. Therefore, along with understanding absorption, distribution, metabolism, and excretion (ADME) through PK evaluation,Evaluate intratumoral distribution and BBB permeabilityand it is important to appropriately differentiate the causes of insufficient drug efficacy by combining this with pharmacological tests.

Evaluate safety from an early stage

Since EGFR is also expressed in normal tissues,Safety assessment considering on-target toxicity is essential.By understanding toxicity risks from the early stages of development, we can reduce the risk of failure in later stages. It is also important to conduct appropriate safety studies according to the modality, such as hERG testing for cardiotoxicity assessment and ADA (anti-drug antibody) evaluation for biopharmaceuticals.

Key points when choosing a contract research organization (CRO) for non-clinical studies

In the development of EGFR inhibitors, pharmacokinetic (PK) evaluation alone is not sufficient. A system capable of consistently addressing efficacy evaluation, safety evaluation, and pathological/resistance models utilizing resistant cell lines, patient-derived organoids, and PDX models is crucial. Selecting a CRO that can provide evaluation systems tailored to the development stage leads to efficient development.